Cambridge, Massachusetts-based Biogen has appointed Dr Paul McKenzie as executive vice president of pharmaceutical operations and technology.
Dr McKenzie will take up the new role and a place on the firm’s management team from 1 July, reporting to chief executive officer Dr George Scangos.
The position will not only include responsibility for asset management, technical development, global manufacturing, supply chain operations and engineering, but also overseeing the construction and operation of a new biologic manufacturing facility in Solothurn, Switzerland.
Dr McKenzie joined Biogen earlier this year as senior vice president of global biologics, manufacturing and technical operations from Johnson & Johnson, where he held a number of leadership roles including vice president of research and development for J&J’s Ethicon business.
Prior to that, Dr McKenzie worked at Janssen and also brings operations and R&D experience from Bristol-Myers Squibb and Merck.
Dr Scangos said: “With his extensive technical and development expertise, we believe Paul is ideally suited to lead the next phase of growth across Biogen’s development and manufacturing operations.
“He will play an essential role, building upon our tradition of world-class manufacturing while leading the development of next generation capabilities to ensure global availability or our current and future therapies.”